• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于超声参数与临床指标相结合的列线图在乳腺癌病理缓解程度中的作用

The Role of Nomogram Based on the Combination of Ultrasound Parameters and Clinical Indicators in the Degree of Pathological Remission of Breast Cancer.

作者信息

Chen Huangjing, Qian Hongyan, Chen Guifang, Zhu Pengfei, Sun Chunjuan, Wu Xiaotian, He Ying

机构信息

Medical College of Nantong University, Nantong 226361, Jiangsu, China.

Key Laboratory of Cancer Research Center Nantong, Tumor Hospital Affiliated to Nantong University, Nantong 226006, Jiangsu, China.

出版信息

J Oncol. 2023 Feb 16;2023:3077180. doi: 10.1155/2023/3077180. eCollection 2023.

DOI:10.1155/2023/3077180
PMID:36844869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9950317/
Abstract

BACKGROUND

The mortality rate of breast cancer (BC) ranks first among female tumors worldwide and presents a trend of younger age, which poses a great threat to women's health and life. Neoadjuvant chemotherapy (NAC) for breast cancer is defined as the first step of treatment for breast cancer patients without distant metastasis before planned surgical treatment or local treatment with surgery and radiotherapy. According to the current NCCN guidelines, patients with different molecular types of BC should receive neoadjuvant chemotherapy (NAC), which can not only achieve tumor downstaging, increase the chance of surgery, and improve the breast-conserving rate. In addition, it can identify new genetic pathways and drugs related to cancer, improve patient survival rate, and make new progress in breast cancer management.

OBJECTIVE

To explore the role of the nomogram established by the combination of ultrasound parameters and clinical indicators in the degree of pathological remission of breast cancer.

METHODS

A total of 147 breast cancer patients who received neoadjuvant chemotherapy and elective surgery in the Department of Ultrasound, Nantong Cancer Hospital, from May 2014 to August 2021 were retrospectively included. Postoperative pathological remission was divided into two groups according to Miller-Payne classification: no significant remission group (NMHR group,  = 93) and significant remission group (MHR group,  = 54). Clinical characteristics of patients were recorded and collected. The multivariate logistic regression model was used to screen the information features related to the MHR group, and then, a nomogram model was constructed; ROC curve area, consistency index (C-index, CI), calibration curve, and H-L test were used to evaluate the model. And the decision curve is used to compare the net income of the single model and composite model.

RESULTS

Among 147 breast cancer patients, 54 (36.7%) had pathological remission. Multivariate logistic regression showed that ER, reduction/disappearance of strong echo halo, Adler classification after NAC, PR + CR, and morphological changes were independent risk factors for pathological remission ( < 0.05). Based on these factors, the nomogram was constructed and verified. The area under the curve (AUC) and CI were 0.966, the sensitivity and specificity were 96.15% and 92.31%, and the positive predictive value (PPV) and negative predictive value (NPV) were 87.72% and 97.15%, respectively. The mean absolute error of the agreement between the predicted value and the real value is 0.026, and the predicted risk is close to the actual risk. In the range of HRT of about 0.0∼0.9, the net benefit of the composite evaluation model is higher than that of the single model. H-L test results showed that  = 8.430, =0.393 > 0.05.

CONCLUSION

The nomogram model established by combining the changes of ultrasound parameters and clinical indicators is a practical and convenient prediction model, which has a certain value in predicting the degree of pathological remission after neoadjuvant chemotherapy.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/5d532f882238/JO2023-3077180.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/c0a5aae80d53/JO2023-3077180.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/ad9970e885d0/JO2023-3077180.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/02e8b318246f/JO2023-3077180.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/ed82961c46c7/JO2023-3077180.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/5d532f882238/JO2023-3077180.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/c0a5aae80d53/JO2023-3077180.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/ad9970e885d0/JO2023-3077180.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/02e8b318246f/JO2023-3077180.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/ed82961c46c7/JO2023-3077180.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9278/9950317/5d532f882238/JO2023-3077180.005.jpg
摘要

背景

乳腺癌(BC)死亡率在全球女性肿瘤中位居首位,且呈现年轻化趋势,对女性健康和生命构成巨大威胁。乳腺癌新辅助化疗(NAC)被定义为在计划手术治疗或手术及放疗的局部治疗前,对无远处转移的乳腺癌患者进行的第一步治疗。根据当前美国国立综合癌症网络(NCCN)指南,不同分子类型的BC患者均应接受新辅助化疗(NAC),其不仅能实现肿瘤降期,增加手术机会,提高保乳率。此外,还能识别与癌症相关的新基因途径和药物,提高患者生存率,在乳腺癌治疗管理方面取得新进展。

目的

探讨超声参数与临床指标联合建立的列线图在乳腺癌病理缓解程度中的作用。

方法

回顾性纳入2014年5月至2021年8月在南通市肿瘤医院超声科接受新辅助化疗及择期手术的147例乳腺癌患者。术后病理缓解根据米勒-佩恩分类分为两组:无显著缓解组(NMHR组,n = 93)和显著缓解组(MHR组,n = 54)。记录并收集患者的临床特征。采用多因素logistic回归模型筛选与MHR组相关的信息特征,进而构建列线图模型;采用受试者工作特征(ROC)曲线下面积、一致性指数(C-index,CI)、校准曲线及Hosmer-Lemeshow(H-L)检验对模型进行评估。并采用决策曲线比较单模型和复合模型的净收益。

结果

147例乳腺癌患者中,54例(36.7%)出现病理缓解。多因素logistic回归显示,雌激素受体(ER)、强回声晕环缩小/消失、新辅助化疗后阿德勒分级、孕激素受体(PR)+细胞周期蛋白依赖性激酶抑制剂1(CR)及形态学改变是病理缓解的独立危险因素(P < 0.05)。基于这些因素构建并验证了列线图。曲线下面积(AUC)及CI为0.966,灵敏度和特异度分别为96.15%和92.31%,阳性预测值(PPV)和阴性预测值(NPV)分别为87.72%和97.15%。预测值与实际值一致性的平均绝对误差为0.026,预测风险接近实际风险。在约0.0~0.9的决策阈值范围内,复合评估模型的净收益高于单模型。H-L检验结果显示,χ² = 8.430,P = 0.393 > 0.05。

结论

超声参数与临床指标变化联合建立的列线图模型是一种实用便捷的预测模型,在预测新辅助化疗后病理缓解程度方面具有一定价值。

相似文献

1
The Role of Nomogram Based on the Combination of Ultrasound Parameters and Clinical Indicators in the Degree of Pathological Remission of Breast Cancer.基于超声参数与临床指标相结合的列线图在乳腺癌病理缓解程度中的作用
J Oncol. 2023 Feb 16;2023:3077180. doi: 10.1155/2023/3077180. eCollection 2023.
2
[Risk factor analysis on anastomotic leakage after laparoscopic surgery in rectal cancer patient with neoadjuvant therapy and establishment of a nomogram prediction model].[新辅助治疗直肠癌患者腹腔镜手术后吻合口漏的危险因素分析及列线图预测模型的建立]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Aug 25;22(8):748-754. doi: 10.3760/cma.j.issn.1671-0274.2019.08.009.
3
Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram.利用列线图通过超声和临床病理特征预测晚期乳腺癌新辅助化疗后的病理完全缓解
Front Oncol. 2021 Nov 23;11:718531. doi: 10.3389/fonc.2021.718531. eCollection 2021.
4
[Establishment and validation of a predictive nomogram model for advanced gastric cancer with perineural invasion].[伴有神经侵犯的进展期胃癌预测列线图模型的建立与验证]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Nov 25;23(11):1059-1066. doi: 10.3760/cma.j.cn.441530-20200103-00004.
5
Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Combining Both Clinicopathological and Imaging Indicators.结合临床病理和影像学指标的乳腺癌新辅助化疗病理完全缓解早期预测列线图
Curr Probl Cancer. 2022 Dec;46(6):100914. doi: 10.1016/j.currproblcancer.2022.100914. Epub 2022 Nov 1.
6
[Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].[初诊为同侧锁骨上淋巴结转移的乳腺癌新辅助化疗后同侧锁骨上淋巴结病理完全缓解(pCR)的列线图预测模型构建]
Zhonghua Zhong Liu Za Zhi. 2022 Feb 23;44(2):160-166. doi: 10.3760/cma.j.cn112152-20200420-00358.
7
A Novel Combined Nomogram Model for Predicting the Pathological Complete Response to Neoadjuvant Chemotherapy in Invasive Breast Carcinoma of No Specific Type: Real-World Study.一种预测非特殊类型浸润性乳腺癌新辅助化疗病理完全缓解的新型联合列线图模型:真实世界研究
Front Oncol. 2022 Jun 6;12:916526. doi: 10.3389/fonc.2022.916526. eCollection 2022.
8
Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.中国多中心回顾性研究:激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌新辅助化疗后乳腺病理完全缓解和无病生存的真实世界数据。
World J Surg Oncol. 2022 Sep 29;20(1):326. doi: 10.1186/s12957-022-02787-9.
9
An ultrasound-based nomogram model in the assessment of pathological complete response of neoadjuvant chemotherapy in breast cancer.一种基于超声的列线图模型在评估乳腺癌新辅助化疗的病理完全缓解中的应用
Front Oncol. 2024 Mar 4;14:1285511. doi: 10.3389/fonc.2024.1285511. eCollection 2024.
10
Ultrasound Strain Elastography and Contrast-Enhanced Ultrasound in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: A Nomogram Integrating Ki-67 and Ultrasound Features.超声应变弹性成像及超声造影在预测乳腺癌新辅助化疗疗效中的价值:整合 Ki-67 及超声特征的列线图
J Ultrasound Med. 2022 Sep;41(9):2191-2201. doi: 10.1002/jum.15900. Epub 2021 Dec 10.

引用本文的文献

1
Multimodal prediction based on ultrasound for response to neoadjuvant chemotherapy in triple negative breast cancer.基于超声的三阴性乳腺癌新辅助化疗反应的多模态预测
NPJ Precis Oncol. 2025 Jul 25;9(1):259. doi: 10.1038/s41698-025-01057-7.
2
Predicting pathological complete response after neoadjuvant chemotherapy in breast cancer by clinicopathological indicators and ultrasound parameters using a nomogram.基于列线图的临床病理指标及超声参数预测乳腺癌新辅助化疗后的病理完全缓解。
Sci Rep. 2024 Jul 16;14(1):16348. doi: 10.1038/s41598-024-64766-2.

本文引用的文献

1
Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram.利用列线图通过超声和临床病理特征预测晚期乳腺癌新辅助化疗后的病理完全缓解
Front Oncol. 2021 Nov 23;11:718531. doi: 10.3389/fonc.2021.718531. eCollection 2021.
2
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.NCCN 指南®洞察:乳腺癌,第 4.2021 版。
J Natl Compr Canc Netw. 2021 May 1;19(5):484-493. doi: 10.6004/jnccn.2021.0023.
3
Effects of contrast-enhanced ultrasound treatment on neoadjuvant chemotherapy in breast cancer.
超声造影治疗对乳腺癌新辅助化疗的影响。
Theranostics. 2021 Sep 21;11(19):9557-9570. doi: 10.7150/thno.64767. eCollection 2021.
4
[Chinese Society of Clinical Oncology Breast Cancer Guideline version 2021: updates and interpretations].《中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2021版:更新与解读》
Zhonghua Yi Xue Za Zhi. 2021 Jun 29;101(24):1835-1838. doi: 10.3760/cma.j.cn112137-20210421-00954.
5
Breast cancer subtypes affect the ultrasound performance for axillary lymph node status evaluation after neoadjuvant chemotherapy: a retrospective analysis.乳腺癌亚型影响新辅助化疗后腋窝淋巴结状态评估的超声表现:一项回顾性分析。
Jpn J Clin Oncol. 2021 Oct 5;51(10):1509-1514. doi: 10.1093/jjco/hyab117.
6
Progress of Breast Cancer basic research in China.中国乳腺癌基础研究进展。
Int J Biol Sci. 2021 May 11;17(8):2069-2079. doi: 10.7150/ijbs.60631. eCollection 2021.
7
Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.影响乳腺癌新辅助化疗后病理完全缓解的因素:预测列线图的建立与验证。
Radiology. 2021 May;299(2):290-300. doi: 10.1148/radiol.2021203871. Epub 2021 Mar 23.
8
Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.基于超声的深度学习放射组学在局部晚期乳腺癌新辅助化疗病理完全缓解评估中的应用。
Eur J Cancer. 2021 Apr;147:95-105. doi: 10.1016/j.ejca.2021.01.028. Epub 2021 Feb 24.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
[Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition)].《中国晚期乳腺癌临床诊疗指南(2020年版)》
Zhonghua Zhong Liu Za Zhi. 2020 Oct 23;42(10):781-797. doi: 10.3760/cma.j.cn112152-20200817-00747.